Macitentan Patent Expiration
Macitentan is used for treating pulmonary arterial hypertension. It was first introduced by Actelion Pharmaceuticals Us Inc
Macitentan Patents
Given below is the list of patents protecting Macitentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Opsumit | US8268847 | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor | Apr 18, 2029 | Actelion |
| Opsumit | US8367685 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | Oct 04, 2028 | Actelion |
| Opsumit | US9265762 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | May 29, 2027 | Actelion |
| Opsumit | US10946015 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | Sep 11, 2026 | Actelion |
| Opsumit | US7094781 | Sulfamides and their use as endothelin receptor antagonists | Dec 05, 2025 | Actelion |
Macitentan's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List